Loading...
•
Dec 31, 2024
Structure Therapeutics Q4 2024 Earnings Report
Estimated Revenue:$0
Estimated EPS:-$0.23
9.5% YoY
Key Takeaways
Structure Therapeutics reported a net loss of $36.479 million for the fourth quarter of 2024, compared to a net loss of $24.503 million in the same period last year. The company's cash, cash equivalents, and short-term investments totaled $883.518 million at year-end 2024, indicating a strong financial position.
Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled, with topline data anticipated by year-end 2025.
Oral small molecule amylin receptor agonist (ACCG-2671) is undergoing IND-enabling activities, with Phase 1 initiation expected by year-end 2025.
The company ended 2024 with a strong financial position, holding $883.5 million in cash, cash equivalents, and short-term investments.
Research and Development expenses increased to $33.487 million in Q4 2024 from $20.042 million in Q4 2023, driven by increased headcount and advancement of the GLP-1R franchise.
Structure Therapeutics
Structure Therapeutics
Forward Guidance
Structure Therapeutics anticipates 2025 to be a transformative year for its oral selective GLP-1 small molecules, with key clinical milestones expected for aleniglipron and ACCG-2671. The company expects its current cash to fund operations and clinical milestones through at least 2027.
Positive Outlook
- 2025 is expected to be a transformative year for oral selective GLP-1 small molecules in obesity and related diseases.
- Aleniglipron is anticipated to have 36-week data by year-end 2025 and a potential best-in-class profile.
- ACCG-2671, an oral amylin receptor agonist, is expected to begin Phase 1 development by year-end 2025.
- The company's cash position is expected to fund projected operations and key clinical milestones through at least 2027.
- Robust pipeline of potential combination therapies currently being investigated.
Challenges Ahead
- Results from earlier clinical studies may not be predictive of future results.
- Potential delays in the commencement, enrollment, and completion of planned clinical studies.
- Ability to obtain regulatory approval and commercialize therapeutic candidates is not guaranteed.
- Reliance on third parties, including clinical research organizations, manufacturers, suppliers, and collaborators, over which the company may not always have full control.
- Impact of global pandemics, inflation, tariffs, supply chain issues, rising interest rates, future bank failures, and other macroeconomic factors on the company's business.
Loading...
Key Statistics
Market Cap
$1.11B
P/E Ratio
-10.44
Sector
Health Technology
Industry
Pharmaceuticals Major
52-Week High
$43.9
52-Week Low
$14.1
Research and Development Expenses
$33.5M
General and Administrative Expenses
$13.6M
Cash, Cash Equivalents and Short-Term Investments
$884M
Share-Based Compensation Expense
$5.8M